Ad
Monday, 20 February 2017
BrainStorm seeks early approval for stem cell treatment in Canada
TEL AVIV (Reuters) - Israel's BrainStorm Cell Therapeutics is seeking early approval in Canada for its adult stem cell treatment for patients with amyotrophic lateral sclerosis (ALS), a neuro-degenerative disease, even before it completes late-stage clinical trials.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment